Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001104659-25-014378
Filing Date
2025-02-14
Accepted
2025-02-14 20:00:35
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 10134
  Complete submission text file 0001104659-25-014378.txt   11953
Mailing Address 47 HULFISH STREET PRINCETON NJ 08542
Business Address 47 HULFISH STREET PRINCETON NJ 08542 (609) 662-2000
AMICUS THERAPEUTICS, INC. (Subject) CIK: 0001178879 (see all company filings)

EIN.: 200422823 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-83043 | Film No.: 25632088
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address ONE LETTERMAN DRIVE BUILDING D, SUITE D3-300 SAN FRANCISCO CA 94129
Business Address ONE LETTERMAN DRIVE BUILDING D, SUITE D3-300 SAN FRANCISCO CA 94129 415-489-9980
Redmile Group, LLC (Filed by) CIK: 0001425738 (see all company filings)

EIN.: 208592298 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A